Systematic review on evidence of the effectiveness of cholesterol-lowering drugs

Abhaya Gupta, Veronique Guyomard, M Justin S Zaman, Habib U Rehman, Phyo Kyaw Myint

Research output: Contribution to journalLiterature review

16 Citations (Scopus)

Abstract

INTRODUCTION: Coronary heart disease (CHD) is the leading cause of mortality worldwide. With increasingly urbanized lifestyles in developing countries and the aging populations, the major risk factors for CHD such as obesity, diabetes mellitus, and hypercholesterolemia are likely to increase in the future. In the current report, we reviewed the evidence on the effect of cholesterol lowering using pharmacological agents.

METHODS: A PubMed/Medline systematic search was performed over the past 12 years (1998-2009 inclusive) and relevant papers written in the English language were selected. We used key phrases including, "risk factors for hypercholesterolemia," "management of hypercholesterolemia," "guidelines for management of hypercholesterolemia," and "pharmacological management of hypercholesterolemia."

RESULTS: There were a total of over 3500 reports. We selected key publications on the effect of cholesterol lowering using different pharmacological agents.

CONCLUSION: Several options exist with regards to pharmacological management of hypercholesterolemia. There is a substantial body of evidence to support the effect of a population shift towards a favorable risk profile, which has huge potential in reducing the burden of CHD globally.

Original languageEnglish
Pages (from-to)348-364
Number of pages17
JournalAdvances in Therapy
Volume27
Issue number6
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Hypercholesterolemia
Cholesterol
Pharmaceutical Preparations
Pharmacology
Coronary Disease
PubMed
Population
Developing Countries
Publications
Life Style
Diabetes Mellitus
Language
Obesity
Guidelines
Mortality

Keywords

  • anticholesteremic agents
  • azetidines
  • cholestyramine resin
  • coronary disease
  • drug therapy, combination
  • evidence-based practice
  • ezetimibe
  • fatty acids, omega-3
  • gemfibrozil
  • humans
  • hydroxymethylglutaryl-CoA reductase inhibitors
  • hypercholesterolemia
  • niacin
  • patient selection
  • phytosterols
  • practice guidelines as topic
  • primary prevention
  • risk assessment
  • risk factors
  • risk reduction behavior
  • secondary prevention
  • treatment outcome

Cite this

Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. / Gupta, Abhaya; Guyomard, Veronique; Zaman, M Justin S; Rehman, Habib U; Myint, Phyo Kyaw.

In: Advances in Therapy, Vol. 27, No. 6, 06.2010, p. 348-364.

Research output: Contribution to journalLiterature review

Gupta, Abhaya ; Guyomard, Veronique ; Zaman, M Justin S ; Rehman, Habib U ; Myint, Phyo Kyaw. / Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. In: Advances in Therapy. 2010 ; Vol. 27, No. 6. pp. 348-364.
@article{eec927c55a6748fdbea197c7ebd33bff,
title = "Systematic review on evidence of the effectiveness of cholesterol-lowering drugs",
abstract = "INTRODUCTION: Coronary heart disease (CHD) is the leading cause of mortality worldwide. With increasingly urbanized lifestyles in developing countries and the aging populations, the major risk factors for CHD such as obesity, diabetes mellitus, and hypercholesterolemia are likely to increase in the future. In the current report, we reviewed the evidence on the effect of cholesterol lowering using pharmacological agents.METHODS: A PubMed/Medline systematic search was performed over the past 12 years (1998-2009 inclusive) and relevant papers written in the English language were selected. We used key phrases including, {"}risk factors for hypercholesterolemia,{"} {"}management of hypercholesterolemia,{"} {"}guidelines for management of hypercholesterolemia,{"} and {"}pharmacological management of hypercholesterolemia.{"}RESULTS: There were a total of over 3500 reports. We selected key publications on the effect of cholesterol lowering using different pharmacological agents.CONCLUSION: Several options exist with regards to pharmacological management of hypercholesterolemia. There is a substantial body of evidence to support the effect of a population shift towards a favorable risk profile, which has huge potential in reducing the burden of CHD globally.",
keywords = "anticholesteremic agents, azetidines, cholestyramine resin, coronary disease, drug therapy, combination, evidence-based practice, ezetimibe, fatty acids, omega-3, gemfibrozil, humans, hydroxymethylglutaryl-CoA reductase inhibitors, hypercholesterolemia, niacin, patient selection, phytosterols, practice guidelines as topic, primary prevention, risk assessment, risk factors, risk reduction behavior, secondary prevention, treatment outcome",
author = "Abhaya Gupta and Veronique Guyomard and Zaman, {M Justin S} and Rehman, {Habib U} and Myint, {Phyo Kyaw}",
year = "2010",
month = "6",
doi = "10.1007/s12325-010-0033-6",
language = "English",
volume = "27",
pages = "348--364",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer",
number = "6",

}

TY - JOUR

T1 - Systematic review on evidence of the effectiveness of cholesterol-lowering drugs

AU - Gupta, Abhaya

AU - Guyomard, Veronique

AU - Zaman, M Justin S

AU - Rehman, Habib U

AU - Myint, Phyo Kyaw

PY - 2010/6

Y1 - 2010/6

N2 - INTRODUCTION: Coronary heart disease (CHD) is the leading cause of mortality worldwide. With increasingly urbanized lifestyles in developing countries and the aging populations, the major risk factors for CHD such as obesity, diabetes mellitus, and hypercholesterolemia are likely to increase in the future. In the current report, we reviewed the evidence on the effect of cholesterol lowering using pharmacological agents.METHODS: A PubMed/Medline systematic search was performed over the past 12 years (1998-2009 inclusive) and relevant papers written in the English language were selected. We used key phrases including, "risk factors for hypercholesterolemia," "management of hypercholesterolemia," "guidelines for management of hypercholesterolemia," and "pharmacological management of hypercholesterolemia."RESULTS: There were a total of over 3500 reports. We selected key publications on the effect of cholesterol lowering using different pharmacological agents.CONCLUSION: Several options exist with regards to pharmacological management of hypercholesterolemia. There is a substantial body of evidence to support the effect of a population shift towards a favorable risk profile, which has huge potential in reducing the burden of CHD globally.

AB - INTRODUCTION: Coronary heart disease (CHD) is the leading cause of mortality worldwide. With increasingly urbanized lifestyles in developing countries and the aging populations, the major risk factors for CHD such as obesity, diabetes mellitus, and hypercholesterolemia are likely to increase in the future. In the current report, we reviewed the evidence on the effect of cholesterol lowering using pharmacological agents.METHODS: A PubMed/Medline systematic search was performed over the past 12 years (1998-2009 inclusive) and relevant papers written in the English language were selected. We used key phrases including, "risk factors for hypercholesterolemia," "management of hypercholesterolemia," "guidelines for management of hypercholesterolemia," and "pharmacological management of hypercholesterolemia."RESULTS: There were a total of over 3500 reports. We selected key publications on the effect of cholesterol lowering using different pharmacological agents.CONCLUSION: Several options exist with regards to pharmacological management of hypercholesterolemia. There is a substantial body of evidence to support the effect of a population shift towards a favorable risk profile, which has huge potential in reducing the burden of CHD globally.

KW - anticholesteremic agents

KW - azetidines

KW - cholestyramine resin

KW - coronary disease

KW - drug therapy, combination

KW - evidence-based practice

KW - ezetimibe

KW - fatty acids, omega-3

KW - gemfibrozil

KW - humans

KW - hydroxymethylglutaryl-CoA reductase inhibitors

KW - hypercholesterolemia

KW - niacin

KW - patient selection

KW - phytosterols

KW - practice guidelines as topic

KW - primary prevention

KW - risk assessment

KW - risk factors

KW - risk reduction behavior

KW - secondary prevention

KW - treatment outcome

U2 - 10.1007/s12325-010-0033-6

DO - 10.1007/s12325-010-0033-6

M3 - Literature review

VL - 27

SP - 348

EP - 364

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 6

ER -